Who We Help

Why Reps With Better Data Still Can't Move Prescribing Habits

Your evidence is stronger than the incumbent's. The detail piece is new. Three quarters in, prescribing looks exactly as it did before.

Book a conversation

What prescribing actually is

A prescribing pattern is not a conclusion a physician reached once and could revisit on request. It is an accumulated position about what protects their patients, built out of training, out of outcomes they personally watched, and out of the specific memory of the last time something went wrong. It sits far closer to identity than to preference.

Which makes the thing you are asking for larger than it looks on a call plan. You are asking a physician to take personal responsibility for a different outcome in a patient who is currently stable. The downside of that lands on them, in their exam room, with their name on it. The upside lands in a study.

What they are deciding is what they want to be true for their patients a year from now, and whether the thing you are describing is how they get there.

What keeps happening instead

Corporate training answers a different question entirely. It certifies the rep on the label, the data, the approved claims, and the detail piece, then measures them on reach and frequency. The rep arrives fully equipped for a conversation about evidence, in a room where evidence was never the constraint.

The window makes it worse. Four minutes in a hallway rewards the most compressed version of the strongest claim, which is exactly what the previous rep also delivered about a different product. The physician is not comparing two arguments at that point. They are recognising a category and filing it.

Meanwhile the incumbent holds something you do not, which is a vivid present. It is working, the patients are stable, and switching introduces a risk that is concrete while your benefit stays statistical. Better data does not beat that, because it is not competing with data.

Physicians who accept the data without contest and prescribe exactly as before
Access measured in calls completed rather than in anything that changed afterward
Being unable to name what would have to be true for a specific physician to switch

What changes when the physician owns the future

The sequence has to invert, and the four-minute window is a reason for that rather than an obstacle to it. The opening question is not about your product. It is about the patients in their panel who are not where the physician wants them, and what they wish were different about that group by next year.

That answer is Vision Lock, and it costs less time than the compressed detail it replaces, because the physician is describing their own practice rather than absorbing yours. It also hands you something no competitor's data has, which is the physician's own words about the outcome they are chasing.

The evidence enters after that, and it enters as Conviction Build. A trial result presented cold is a claim to be weighed. The same result presented against a future the physician has already named is the mechanism for that future. Nothing about the data changed. What it attaches to did.

Belief repair matters here more than in most categories, because there is almost always a reason this physician stopped believing something like this was possible. Naming that history tends to be far more productive than adding another study to the pile.

Where the patient conversation multiplies the rep

The chain does not end at the physician. It runs on to the patient, and the patient decides whether any of this actually happens, through adherence, through follow-up, and through whether they understood what changes for them or simply left with a prescription.

Physicians are increasingly judged on that back end. Outcomes, adherence, the numbers their group reports. So a rep who helps a practice explain what a patient is walking toward, rather than what a molecule does, is working directly on the measure the physician is held accountable for.

That is a different relationship than a detail piece produces. The reps who become genuinely difficult to displace are not the ones carrying the best data. They are the ones a practice would have to give something up to replace.

Common questions

Why doesn't better clinical data change prescribing?

Because prescribing is not primarily a data position. It is an accumulated judgment about patient safety that a physician holds personally and defends personally. Data can confirm a decision a physician is already moving toward, and it very rarely creates the movement. Presented into a settled habit, the strongest evidence in the category still reads as one more claim in a stack of claims.

What should a four-minute call open with instead of the detail piece?

A question about the physician's own patients rather than a statement about your product. Which patients in their panel are not where they want them, and what they wish were different about that group. It takes under a minute, it produces the physician's own language about the outcome they want, and everything said afterward attaches to that instead of competing with the incumbent for attention.

How do you compete against an incumbent habit that is working?

Not by attacking it, which puts the physician in the position of defending a decision they already made. The opening is the gap between where the current approach gets patients and where the physician actually wants them, in their words. An incumbent that is working is still not delivering the future the physician described, and that distance is the only thing worth talking about.

Go deeper

Your reps are certified on the data. This is the conversation the data belongs in.

We work with pharmaceutical teams on the sequence that comes before the detail piece, so the evidence lands on a future the physician already named.

Explore engagements